Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company is headquartered in West Conshohocken, Pennsylvania. Show more

Location: Four Tower Bridge, West Conshohocken, PA, 19428, United States | Website: https://www.madrigalpharma.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

9.702B

52 Wk Range

$200.63 - $443.00

Previous Close

$435.27

Open

$436.30

Volume

254,627

Day Range

$426.00 - $438.74

Enterprise Value

9.029B

Cash

797M

Avg Qtr Burn

-76.85M

Insider Ownership

7.67%

Institutional Own.

-

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.